Alamar Biosciences (ALMR.US) began trading on the U.S. stock market on Friday, with its share price opening more than 34% higher at $22.91. The IPO price was set at $17 per share. Alamar Biosciences is a biotechnology company based in California, focused on the development and application of precision proteomics technologies. The company's core products are built on its proprietary NULISA platform, which enables the detection of trace protein biomarkers in blood with extremely high sensitivity. This technology assists researchers in earlier disease detection and advances drug development and precision medicine. Its applications are primarily in the research of neurodegenerative diseases such as Alzheimer's and Parkinson's.